Skip to main content
. 2020 Jan 21;111(2):528–535. doi: 10.1111/cas.14252

Figure 3.

Figure 3

Predicted median objective response rate (ORR) based on 240 mg Q2W or 3 mg/kg Q2W dosing in patients from Japanese studies and with the following tumor types: melanoma (A); squamous non–small cell lung cancer (SQ‐NSCLC) (B); non–squamous non–small cell lung cancer (NSQ‐NSCLC) (C). Q2W, every 2 wk